#65 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to understand that current evidence does not support cannabis use for anxiety or depression, yet patients are increasingly self-treating with these products based on perceived benefits. Without robust clinical trial data demonstrating efficacy, prescribing or endorsing cannabis for mood disorders exposes patients to potential harms including dependence, cognitive effects, and drug interactions while delaying evidence-based treatments like SSRIs or therapy. Clinicians should counsel patients seeking cannabis for mental health that FDA-approved medications remain the standard of care until higher-quality evidence emerges.
Despite widespread patient use of cannabis for anxiety and depression, current scientific evidence does not support efficacy for these mental health conditions, and most clinical trials examining cannabinoid treatments for psychiatric disorders have failed to demonstrate meaningful benefit. While cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) are the primary active compounds in medical cannabis products, robust randomized controlled trials establishing their safety and efficacy for mood and anxiety disorders remain lacking. In fact, some evidence suggests that THC may worsen anxiety and depressive symptoms in certain populations, while CBD research remains preliminary and inconclusive for psychiatric applications. This evidence gap is particularly concerning given the growing number of patients self-medicating with cannabis for mental health without medical supervision. Clinicians should counsel patients seeking cannabis for anxiety or depression about the absence of strong scientific support, discuss established first-line treatments with proven efficacy, and monitor patients who choose to use cannabis for psychiatric symptoms. Patients and providers should base treatment decisions on evidence-based therapies rather than anecdotal reports, while awaiting higher-quality clinical trials that may eventually clarify the role, if any, of cannabinoids in psychiatric care.
“The clinical reality is that while patients report subjective symptom relief with cannabis, our randomized controlled trials simply don’t support efficacy for anxiety or depression at doses patients can tolerate without adverse effects, and the risk of dependence or worsening anxiety with regular use remains real and underappreciated in current practice.”
? While cannabis use for anxiety and depression is increasingly common among patients, clinicians should be aware that robust clinical evidence supporting these indications remains limited, with most research showing mixed or inconclusive results. The heterogeneity of cannabis products, variable ratios of CBD to THC, differing routes of administration, and lack of standardized dosing further complicate interpretation of available studies and make it difficult to counsel patients on safety and efficacy. Additionally, THC’s psychoactive properties may actually worsen anxiety or trigger psychotic symptoms in vulnerable populations, while potential dependencies and cognitive effects warrant careful consideration in long-term use. When patients ask about cannabis for mood or anxiety symptoms, clinicians should acknowledge the current evidence gap, encourage discussion of established first-line treatments (psychotherapy, SSRIs, or other guideline-recommended agents), and consider cannabis only after shared decision-making that explicitly addresses the lack of proven benefit and documented risks. Documentation of
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
